HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
SGRY
Surgery Partners, Inc.
SGRY lost money over the past year, so it has no meaningful PE right now. Analysts expect earnings to hold roughly steady.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
SGRY Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Stable | |
| Weak |
SGRY's revenue, profitability and cash flow are currently stable, but its balance sheet is weak.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
SGRY PE Valuation
SGRY has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
SGRY Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Decline | |
| Strongly weakening | |
| Limited | |
| Moderate |
Analysts expect SGRY's revenue and profitability to decline, with its earnings holding steady.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
SGRY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.35 | — |
| Q3 2026 | -$0.67 | +$0.69 |
| Q2 2026 | -$0.69 | +$0.74 |
| Q1 2026 | -$0.59 | +$0.94 |
| Q4 2025 | -$0.61 | +$0.72 |
| Q3 2025 | -$1.36 | -$0.89 |
| Q2 2025 | -$1.43 | -$1.17 |
| Q1 2025 | -$1.53 | -15400% |
| Q4 2024 | -$1.33 | -$1.24 |
SGRY is still losing money, but far less than before: $0.67 per share over the past year, against $3.67 at its worst in late 2020.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over SGRY on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
SGRY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $815.3M | -0.8% |
| Q2 2026 | $848.9M | +2.7% |
| Q1 2026 | $810.9M | +4.5% |
| Q4 2025 | $885M | +2.4% |
| Q3 2025 | $821.5M | +6.6% |
| Q2 2025 | $826.2M | +8.4% |
| Q1 2025 | $776M | +8.2% |
| Q4 2024 | $864.4M | +18% |
SGRY's revenue grew through 2024 and has held roughly level since: $815M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 11% | -2.4 points |
| Q2 2026 | 12% | -1.5 points |
| Q1 2026 | 8.1% | +0.1 points |
| Q4 2025 | 12% | -2.3 points |
| Q3 2025 | 13% | +5 points |
| Q2 2025 | 14% | +2.4 points |
| Q1 2025 | 8% | -2.6 points |
| Q4 2024 | 15% | +0.9 points |
SGRY has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over SGRY on cash flow, with more consistent year-over-year improvement.
SGRY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $79M | +24% |
| Q2 2026 | $37.5M | -35% |
| Q1 2026 | -$4.3M | +$12.4M |
| Q4 2025 | $90.6M | +1.7% |
| Q3 2025 | $63.8M | +42% |
| Q2 2025 | $57.9M | +3.6% |
| Q1 2025 | -$16.7M | -185% |
| Q4 2024 | $89.1M | +108% |
SGRY generated $203M in free cash flow over the past year, up 4.5% from the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over SGRY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
SGRY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | +40K shares |
| 1 year | +1.3% | +1.7M shares |
| 3 years | +2.5% | +3.1M shares |
| 5 years | +86% | +59.6M shares |
| Available history | +167% | +80.6M shares |
SGRY has 129M diluted shares, up 1.3% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
SGRY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 5.0x | High |
| Q2 2026 | 6.3x | High |
| Q1 2026 | 6.2x | High |
| Q4 2025 | 6.1x | High |
| Q3 2025 | 6.0x | High |
| Q2 2025 | 6.4x | High |
| Q1 2025 | 6.8x | High |
| Q4 2024 | 6.2x | High |
SGRY's net debt is about 5.0 years of its operating earnings (EBITDA), down from 6.0 years a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
SGRY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 79.5 | Overbought |
| Stochastic | 97.4 | Overbought |
SGRY's weekly RSI is 79 (overbought) and its Stochastic is 97 (overbought).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
SGRY PE vs Healthcare Sector
| Metric | SGRY | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
SGRY has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
SGRY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $18.1 | 47% above |
| 20 week MA | $16.3 | 63% above |
| 50 week MA | $15.2 | 75% above |
| 100 week MA | $18.6 | 43% above |
| 200 week MA | $25.0 | 6.5% above |
SGRY has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
SGRY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $15.5 | $27.8 | +79% |
| 2021 | $27.8 | $53.5 | +92% |
| 2022 | $53.5 | $26.7 | -50% |
| 2023 | $26.7 | $32.0 | +20% |
| 2024 | $32.0 | $20.9 | -35% |
| 2025 | $20.9 | $15.9 | -24% |
| 2026 YTD | $15.9 | $26.6 | +67% |
SGRY has the edge over HIMS on returns for 2026, with the stronger performance.